SELES, M., G. C. HUTTERER, J. FOSSELTEDER, Marek SVOBODA, M. RESEL, D. A. BARTH, R. PICHLER, T. BAUERNHOFER, R. E. ZIGEUNER, K. PUMMER, Ondřej SLABÝ, C. KLEC a M. PICHLER. Long Non-Coding RNA PANTR1 is Associated with Poor Prognosis and Influences Angiogenesis and Apoptosis in Clear-Cell Renal Cell Cancer. Cancers. BASEL: MDPI, 2020, roč. 12, č. 5, s. 1-17. ISSN 2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers12051200.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Long Non-Coding RNA PANTR1 is Associated with Poor Prognosis and Influences Angiogenesis and Apoptosis in Clear-Cell Renal Cell Cancer
Autoři SELES, M., G. C. HUTTERER, J. FOSSELTEDER, Marek SVOBODA (203 Česká republika, domácí), M. RESEL, D. A. BARTH, R. PICHLER, T. BAUERNHOFER, R. E. ZIGEUNER, K. PUMMER, Ondřej SLABÝ (203 Česká republika, domácí), C. KLEC (garant) a M. PICHLER.
Vydání Cancers, BASEL, MDPI, 2020, 2072-6694.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 6.639
Kód RIV RIV/00216224:14740/20:00118647
Organizační jednotka Středoevropský technologický institut
Doi http://dx.doi.org/10.3390/cancers12051200
UT WoS 000539246000141
Klíčová slova anglicky long intergenic non-coding RNA; PANTR1; Linc01158; Linc-POU3F3; siRNA; renal cell cancer; clear-cell renal cell carcinoma; oncogene
Štítky 14110513, podil, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 26. 4. 2021 13:47.
Anotace
POU3F3 adjacent non-coding transcript 1 (PANTR1) is an oncogenic long non-coding RNA with significant influence on numerous cellular features in different types of cancer. No characterization of its role in renal cell carcinoma (RCC) is yet available. In this study, PANTR1 expression was confined to human brain and kidney tissue and was found significantly up-regulated in clear-cell renal cell carcinoma tissue (ccRCC) compared to non-cancerous kidney tissue in two independent cohorts (p < 0.001 for both cohorts). In uni- and multivariate Cox regression analysis, ccRCC patients with higher levels of PANTR1 showed significantly poorer disease-free survival in our own respective cohort (n = 175, hazard ratio: 4.3, 95% confidence interval: 1.45-12.75, p = 0.008) in accordance with significantly poorer overall survival in a large The Cancer Genome Atlas database (TCGA) cohort (n = 530, hazard ratio: 2.19, 95% confidence interval: 1.59-3.03, p 0.001). To study the underlying cellular mechanisms mediated by varying levels of PANTR1 in kidney cancer cells, we applied siRNA-mediated knock-down experiments in three independent ccRCC cell lines (RCC-FG, RCC-MF, 769-P). A decrease in PANTR1 levels led to significantly reduced cellular growth through activation of apoptosis in all tested cell lines. Moreover, as angiogenesis is a critical driver in ccRCC pathogenesis, we identified that PANTR1 expression is critical for in vitro tube formation and endothelial cell migration (p < 0.05). On the molecular level, knock-down of PANTR1 led to a decrease in Vascular Endothelial growth factor A (VEGF-A) and cell adhesion molecule laminin subunit gamma-2 (LAMC2) expression, corroborated by a positive correlation in RCC tissue (for VEGF-A R = 0.19, p < 0.0001, for LAMC2 R = 0.13, p = 0.0028). In conclusion, this study provides first evidence that PANTR1 has a relevant role in human RCC by influencing apoptosis and angiogenesis.
Návaznosti
NV18-03-00554, projekt VaVNázev: Molekulární klasifikace renálního buněčného karcinomu založená na expresi dlouhých nekódujících RNA a její využití v diagnostice, předpovědi prognózy a terapii
Investor: Ministerstvo zdravotnictví ČR, Molecular classification of renal cell carcinoma based on long noncoding RNAs expression and its implication for diagnosis, prognosis and therapy
824036, interní kód MUNázev: Excellence in research and development of non-coding RNA DIAGnostics in ONcology (Akronym: RNADIAGON)
Investor: Evropská unie, Excellence in research and development of non-coding RNA DIAGnostics in ONcology, MSCA Marie Skłodowska-Curie Actions (Excellent Science)
90125, velká výzkumná infrastrukturaNázev: BBMRI-CZ III
VytisknoutZobrazeno: 24. 4. 2024 17:12